Show simple item record

dc.contributor.authorYang, Zhaoen_US
dc.contributor.authorLiu, Shengwuen_US
dc.contributor.authorZhu, Mingaoen_US
dc.contributor.authorZhang, Hongen_US
dc.contributor.authorWang, Jien_US
dc.contributor.authorXu, Qianen_US
dc.contributor.authorLin, Kaisuen_US
dc.contributor.authorZhou, Xiuminen_US
dc.contributor.authorTao, Minen_US
dc.contributor.authorLi, Chongen_US
dc.contributor.authorZhu, Hongen_US
dc.date.accessioned2016-04-01T15:47:22Z
dc.date.issued2016en_US
dc.identifier.citationYang, Z., S. Liu, M. Zhu, H. Zhang, J. Wang, Q. Xu, K. Lin, et al. 2016. “PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathway.” Scientific Reports 6 (1): 22090. doi:10.1038/srep22090. http://dx.doi.org/10.1038/srep22090.en
dc.identifier.issn2045-2322en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:26318509
dc.description.abstractHepatocellular carcinoma (HCC) and colorectal cancer (CRC) are among the most common cancers across the world. Particularly, a large number of patients with CRC also have liver metastasis. Currently, there are just a few targeted drugs against these two kinds of tumors which can only benefit a very small population of patients. Therefore, the need of more effective therapeutic drugs or strategies for these two types of cancers is urgent. PS341 (Bortezomib) is the first proteasome inhibitor drug which has been approved in clinical treatment for multiple myeloma. Here we demonstrated that PS341 negatively regulated HCC and CRC both in vitro and in vivo, including the inhibition of cell proliferation, epithelial-mesenchymal transition (EMT), the expression of stemness-related genes, cell migration and invasiveness. Mechanically, PS341 upregulated the expression of FOXO3, which inhibited the transcriptional activation of CTNNB1. The downregualtion of CTNNB1 led to apoptosis, cell cycle arrest, and the inhibition of migration, invasion, self-renewal and tumor formation of these two cancer types. In sum, our findings shed light on the PS341 mediated targeted therapy against both HCC and CRC in the future.en
dc.language.isoen_USen
dc.publisherNature Publishing Groupen
dc.relation.isversionofdoi:10.1038/srep22090en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768146/pdf/en
dash.licenseLAAen_US
dc.titlePS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3/CTNNB1 signaling pathwayen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalScientific Reportsen
dash.depositing.authorLiu, Shengwuen_US
dc.date.available2016-04-01T15:47:22Z
dc.identifier.doi10.1038/srep22090*
dash.authorsorderedfalse
dash.contributor.affiliatedLiu, Shengwu


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record